GE Johnson Construction Company and CRB broke ground on a multi-structure expansion project at a ceremony attended by more than 150 people.
The first phase of the project will allow Agilent to more than double current production capacity, with opportunities for expansion.
The construction phase is expected to reach completion in late 2017, with considerations made for future phases.
Josh Kunert, CRB project manager, said it was exciting to be involved in the growing oligonucleotide production industry.
“CRB has been involved in design projects within this industry since the early 90s, so it is exciting to see a company like Agilent investing in this technology and all of its potential life-saving treatment applications.”
CRB will lead the design and engineering, while GE Johnson Construction Company will do construction management and general contracting duties.
Jim Johnson, CEO of GE Johnson, said the relationship with Agilent began a few years ago.
“GE Johnson has long been active in this market sector, and we look forward to further developing our expertise with top-notch project partners like Agilent and CRB.”